Novo Nordisk has received an approval of the price from Japan's Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare, and is set to launch Tresiba (insulin degludec) in Japan.
Tresiba is the new once-daily basal insulin with an ultra-long duration of action for the treatment of type 1 and type 2 diabetes.
Tresiba successfully achieved equivalent reductions in HbA1c and was associated with significantly lower risk of night-time hypoglycaemia in the treat-to-target studies.
Tresiba will be made available in Novo Nordisk's latest prefilled insulin pen with an easy push-button FlexTouch and in Penfill, designed for used with Novo Nordisk's insulin delivery systems.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/novo-nordisk-to-launch-new-diabetes-therapy-in-japan-150213
